Logo

INTS

Intensity Therapeutics, Inc.

INTS

Intensity Therapeutics, Inc. • NASDAQ
$0.40 ▲ 0.76% (+0.00)
Market Cap $18.83 M
52w High $3.18
52w Low $0.18
Dividend Yield 0%
P/E -0.73
Volume 497.80K
Outstanding Shares 47.15M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $2.733M ▲ $-2.671M ▼ 0% $-0.06 ▲ $62K ▲
Q2-2025 $0 $2.705M ▼ $-2.537M ▲ 0% $-0.13 ▲ $-2.705M ▲
Q1-2025 $0 $3.394M ▲ $-3.347M ▼ 0% $-0.22 $-3.394M ▼
Q4-2024 $0 $3.203M ▼ $-3.181M ▲ 0% $-0.22 ▲ $-3.181M ▲
Q3-2024 $0 $3.57M $-3.513M 0% $-0.25 $-3.513M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $7.067M ▲ $9.585M ▲ $2.363M ▲ $7.222M ▲
Q2-2025 $2.216M ▲ $4.443M ▲ $2.259M ▼ $2.184M ▲
Q1-2025 $929K ▼ $3.065M ▼ $2.731M ▲ $334K ▼
Q4-2024 $2.59M ▼ $4.783M ▼ $1.865M ▼ $2.918M ▲
Q3-2024 $2.782M $5.213M $2.434M $2.779M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.671M ▼ $-2.387M ▲ $0 $7.238M ▲ $4.851M ▲ $-2.387M ▲
Q2-2025 $-2.537M ▲ $-2.456M ▼ $0 $3.743M ▲ $1.287M ▲ $-2.456M ▼
Q1-2025 $-3.347M ▼ $-1.989M ▲ $0 $328K ▼ $-1.661M ▼ $-1.989M ▲
Q4-2024 $-3.181M ▲ $-2.668M ▲ $0 ▼ $2.476M ▲ $-192K ▲ $-2.668M ▲
Q3-2024 $-3.513M $-3.972M $3.1M $413K $-459K $-3.972M

Five-Year Company Overview

Income Statement

Income Statement INTS is a classic pre‑revenue biotech: it has not generated product or licensing revenue over the past several years. The income statement is driven almost entirely by research and corporate operating expenses, which has led to steady net losses each year. Per‑share losses have been meaningful and have generally widened over time, reflecting ongoing spending without any offsetting income. This is normal for a late‑stage clinical biotech, but it means the business currently depends on external funding rather than internal profit generation.

Balance Sheet

Balance Sheet The balance sheet is very light, with a small base of assets and cash and no reported debt. Equity has moved around and has at times been thin or even negative, which signals that accumulated losses have largely consumed the company’s historic capital base. The lack of debt reduces financial leverage risk, but the limited asset and cash cushion also means the balance sheet does not provide a large safety buffer. Future strength will depend heavily on the company’s ability to raise additional capital as it advances its clinical programs.

Cash Flow

Cash Flow Cash flows are negative and driven by operating outflows tied to research, trials, and overhead. There is essentially no spending on physical assets, so cash burn is almost entirely from day‑to‑day operations. With no operating inflows from revenue, the company must rely on financing transactions or new capital raises to replenish cash. The key cash‑flow question going forward is how long existing resources can support clinical development before additional funding is required, and on what terms that funding might be available.

Competitive Edge

Competitive Edge Competitively, INTS is a small but focused player in oncology, built around its DfuseRx platform and lead asset INT230‑6. Its approach—directly injecting a specialized chemotherapy formulation into tumors to both kill cancer cells and stimulate the immune system—gives it a differentiated scientific story in a crowded cancer field. Patent protection across multiple countries, along with clinical collaborations with large pharma companies, provides some validation and a degree of moat. That said, the company competes against far larger and better‑funded oncology players, and ultimate competitive strength will depend on whether late‑stage clinical results show clear, meaningful benefits versus existing therapies.

Innovation and R&D

Innovation and R&D Innovation is the core of the INTS story. The DfuseRx platform uses specially designed molecules to help traditional chemotherapy drugs spread more evenly inside solid tumors, with the goal of stronger local tumor kill and a broader immune response throughout the body. The lead drug candidate, INT230‑6, has shown encouraging safety and immune‑activation signals in early and mid‑stage studies, and it is now being tested in a pivotal trial for metastatic sarcoma and earlier‑stage work in breast and other cancers. Partnerships with companies like Merck and Bristol Myers Squibb around combination therapies add scientific credibility and potential future leverage. However, all of this remains in the development stage, so there is substantial scientific, regulatory, and execution uncertainty until large, definitive trials read out.

Summary

INTS is an early‑stage, oncology‑focused biotech with no current revenues, persistent losses, and a very lean balance sheet, typical of a company still in the clinical development phase. Its value proposition rests almost entirely on the success of its DfuseRx platform and lead drug INT230‑6, which aim to reshape how chemotherapy is delivered into tumors and how the immune system is engaged. Strong intellectual property, a differentiated mechanism, and collaborations with major pharma players are clear positives, but they are balanced by the usual risks of drug development: clinical failure, regulatory hurdles, funding needs, and intense competition from larger cancer‑therapy companies. The story is high‑risk and highly dependent on future trial outcomes and financing conditions, rather than on current financial performance.

NEWS

November 6, 2025 · 4:02 PM UTC

Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Read more

October 31, 2025 · 8:00 AM UTC

Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock

Read more

October 30, 2025 · 7:30 AM UTC

Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal

Read more

September 10, 2025 · 7:47 AM UTC

Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update

Read more

September 2, 2025 · 7:47 AM UTC

Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Read more